ArticleCurrent opinion in chemical engineering2014
DNA Aptamer Technology for Personalized Medicine.
Article in Current opinion in chemical engineering, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 55 citations in OpenAlex.
- Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy.Clinical and experimental medicine · 2025Review
- Review
- Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development.Molecules (Basel, Switzerland) · 2024Review
- Modular Fabrication of Bioorthogonal Nanozymes for Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Binding Affinity Measurements Between DNA Aptamers and their Virus Targets Using ELONA and MST.Bio-protocol · 2022Article
- Overcoming Major Barriers to Developing Successful Sensors for Practical Applications Using Functional Nucleic Acids.Annual review of analytical chemistry (Palo Alto, Calif.) · 2022Review
- Overcoming the limitations of COVID-19 diagnostics with nanostructures, nucleic acid engineering, and additive manufacturing.Current opinion in solid state & materials science · 2022Article
- Progress in cancer drug delivery based on AS1411 oriented nanomaterials.Journal of nanobiotechnology · 2022Review
- Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.3 Biotech · 2020Review
- Metal-Dependent DNAzymes for the Quantitative Detection of Metal Ions in Living Cells: Recent Progress, Current Challenges, and Latest Results on FRET Ratiometric Sensors.Inorganic chemistry · 2019Review
- Aptamers as Diagnostic Tools in Cancer.Pharmaceuticals (Basel, Switzerland) · 2018Review
- DNA-Encoded Morphological Evolution of Bimetallic Pd@Au Core-shell Nanoparticles from a High-indexed Core.Nano research · 2018Article
- DNA Aptamer-Based Activatable Probes for Photoacoustic Imaging in Living Mice.Journal of the American Chemical Society · 2017Article
- DNA Aptamers in the Diagnosis and Treatment of Human Diseases.Molecules (Basel, Switzerland) · 2015Review
- Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.Biomaterials · 2015Article
- Surface Enzyme Chemistries for Ultrasensitive Microarray Biosensing with SPR Imaging.Langmuir : the ACS journal of surfaces and colloids · 2015Article
- Peptide aptamers: development and applications.Current topics in medicinal chemistry · 2015Review
- Applications of synchrotron-based spectroscopic techniques in studying nucleic acids and nucleic acid-functionalized nanomaterials.Advanced materials (Deerfield Beach, Fla.) · 2014Review
- A DNA aptamer with high affinity and specificity for molecular recognition and targeting therapy of gastric cancer.BMC cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
This review highlights recent progress in developing DNA aptamers for personalized medicine, with more focus on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.